| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ching-Chi Chang, Tzu-Chin Lin, Hsiao-Li Ho, Chien-Yin Kuo, Hsin-Hua Li, Tatiana A Korolenko, Wei-Jen Chen, Te-Jen Lai, Ying-Jui Ho, Chih-Li Li. GLP-1 Analogue Liraglutide Attenuates Mutant Huntingtin-Induced Neurotoxicity by Restoration of Neuronal Insulin Signaling. International journal of molecular sciences. vol 19. issue 9. 2018-12-11. PMID:30149534. |
glp-1 analogue liraglutide attenuates mutant huntingtin-induced neurotoxicity by restoration of neuronal insulin signaling. |
2018-12-11 |
2023-08-13 |
Not clear |
| Ching-Chi Chang, Tzu-Chin Lin, Hsiao-Li Ho, Chien-Yin Kuo, Hsin-Hua Li, Tatiana A Korolenko, Wei-Jen Chen, Te-Jen Lai, Ying-Jui Ho, Chih-Li Li. GLP-1 Analogue Liraglutide Attenuates Mutant Huntingtin-Induced Neurotoxicity by Restoration of Neuronal Insulin Signaling. International journal of molecular sciences. vol 19. issue 9. 2018-12-11. PMID:30149534. |
however, treatment with liraglutide, a glp-1 analogue, markedly restores insulin sensitivity and enhances cell viability. |
2018-12-11 |
2023-08-13 |
Not clear |
| Ching-Chi Chang, Tzu-Chin Lin, Hsiao-Li Ho, Chien-Yin Kuo, Hsin-Hua Li, Tatiana A Korolenko, Wei-Jen Chen, Te-Jen Lai, Ying-Jui Ho, Chih-Li Li. GLP-1 Analogue Liraglutide Attenuates Mutant Huntingtin-Induced Neurotoxicity by Restoration of Neuronal Insulin Signaling. International journal of molecular sciences. vol 19. issue 9. 2018-12-11. PMID:30149534. |
our findings collectively suggest that liraglutide can rescue impaired insulin signaling caused by mhtt and that glp-1 may potentially reduce mhtt-induced neurotoxicity in the pathogenesis of hd. |
2018-12-11 |
2023-08-13 |
Not clear |
| Yehuda Handelsman, Kathleen Wyne, Anthony Cannon, Michael Shannon, Doron Schneide. Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists. Journal of managed care & specialty pharmacy. vol 24. issue 9-a Suppl. 2018-12-11. PMID:30156445. |
glp-1 ras stimulate pancreatic glp-1 receptors, which increases insulin secretion, delays gastric emptying, and increases satiety. |
2018-12-11 |
2023-08-13 |
Not clear |
| Yehuda Handelsman, Kathleen Wyne, Anthony Cannon, Michael Shannon, Doron Schneide. Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists. Journal of managed care & specialty pharmacy. vol 24. issue 9-a Suppl. 2018-12-11. PMID:30156445. |
once-weekly glp-1 ras have also been evaluated as add-on therapy in the continuum of care for the treatment of t2dm in combination with a variety of background medications, including 1 or more oads (metformin, sulfonylureas, and/or thiazolidinediones), basal insulin, and prandial insulin. |
2018-12-11 |
2023-08-13 |
Not clear |
| Yehuda Handelsman, Kathleen Wyne, Anthony Cannon, Michael Shannon, Doron Schneide. Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists. Journal of managed care & specialty pharmacy. vol 24. issue 9-a Suppl. 2018-12-11. PMID:30156445. |
rates of hypoglycemia, and especially major/severe hypoglycemia, are low with once-weekly glp-1 ras but, as expected, are higher when used in combination with sulfonylureas or insulin. |
2018-12-11 |
2023-08-13 |
Not clear |
| Liana K Billings, Yehuda Handelsman, Michael Heile, Doron Schneider, Kathleen Wyn. Health-Related Quality of Life Assessments with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus. Journal of managed care & specialty pharmacy. vol 24. issue 9-a Suppl. 2018-12-11. PMID:30156447. |
compared with oral antihyperglycemic drugs, insulin, and daily glp-1 ras, once-weekly glp-1 ras offer benefits with regard to hrqol and treatment satisfaction. |
2018-12-11 |
2023-08-13 |
Not clear |
| Sheila A Doggrel. Do glucagon-like peptide-1 receptor (GLP-1R) agonists have potential as adjuncts in the treatment of type 1 diabetes? Expert opinion on pharmacotherapy. vol 19. issue 15. 2018-12-11. PMID:30234389. |
glucagon-like peptide-1 (glp-1) is produced by the gut, stimulates insulin secretion from the pancreatic β-cells, and inhibits glucagon secretion from the α-cells. |
2018-12-11 |
2023-08-13 |
Not clear |
| J-H Liou, Y-M Liu, C-H Che. Management of Diabetes Mellitus With Glucagonlike Peptide-1 Agonist Liraglutide in Renal Transplant Recipients: A Retrospective Study. Transplantation proceedings. vol 50. issue 8. 2018-12-11. PMID:30316386. |
liraglutide, a glp-1 receptor agonist, stimulates insulin secretion and inhibits glucagon secretion and hepatic glucose production in a glucose-dependent manner. |
2018-12-11 |
2023-08-13 |
Not clear |
| Carlos Tavares Bello, Ricardo Castro Fonseca, Francisco Sousa Santos, João Sequeira Duarte, Jorge Azinheira, Carlos Vasconcelo. Renal function markers and metformin eligibility. Minerva endocrinologica. vol 43. issue 3. 2018-11-26. PMID:28565889. |
it belongs to the biguanide class of drugs and it improves hepatic insulin resistance and enhances glp-1 and peptide yy secretion. |
2018-11-26 |
2023-08-13 |
Not clear |
| Maka S Hedrington, Ana Tsiskarishvili, Stephen N Davi. Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes. Expert opinion on biological therapy. vol 18. issue 3. 2018-11-19. PMID:29431519. |
the glp-1 receptor agonists stimulate glucose-dependent insulin release (low risk of hypoglycemia), inhibit glucagon secretion, slow gastric emptying and suppress appetite (weight loss). |
2018-11-19 |
2023-08-13 |
Not clear |
| P Larraufie, C Martin-Gallausiaux, N Lapaque, J Dore, F M Gribble, F Reimann, H M Blottier. SCFAs strongly stimulate PYY production in human enteroendocrine cells. Scientific reports. vol 8. issue 1. 2018-11-16. PMID:29311617. |
peptide-yy (pyy) and glucagon-like peptide-1 (glp-1) play important roles in the regulation of food intake and insulin secretion, and are of translational interest in the field of obesity and diabetes. |
2018-11-16 |
2023-08-13 |
mouse |
| Weijia Xie, Xiaoxiao Song, Zhenjie Li. Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases. Vascular pharmacology. vol 109. 2018-11-14. PMID:29879463. |
dipeptidyl peptidase 4 (dpp-4) inhibitor is a novel group of medicine employed in type 2 diabetes mellitus (t2dm),which improves meal stimulated insulin secretion by protecting glucagon-like peptide-1 (glp-1) and glucose dependent insulinotropic polypeptide (gip) from enzymatic degradation. |
2018-11-14 |
2023-08-13 |
Not clear |
| Daniéla Oliveira Magro, Everton Cazzo, Paulo Gustavo Kotze, Ana Carolina Junqueira Vasques, Carlos Augusto Real Martinez, Elinton Adami Chaim, Bruno Geloneze, José Carlos Pareja, Cláudio Saddy Rodrigues Co. Glucose Metabolism Parameters and Post-Prandial GLP-1 and GLP-2 Release Largely Vary in Several Distinct Situations: a Controlled Comparison Among Individuals with Crohn's Disease and Individuals with Obesity Before and After Bariatric Surgery. Obesity surgery. vol 28. issue 2. 2018-11-09. PMID:28776152. |
this study aims to compare the post-prandial curves of glucose, insulin, glp-1, and glp-2 among individuals with crohn's disease (cd), obese individuals before and after bariatric surgery, and healthy controls. |
2018-11-09 |
2023-08-13 |
Not clear |
| Bo-Ram Kim, Hyo Young Kim, Inhee Choi, Jin-Baek Kim, Chang Hyun Jin, Ah-Reum Ha. DPP-IV Inhibitory Potentials of Flavonol Glycosides Isolated from the Seeds of Molecules (Basel, Switzerland). vol 23. issue 8. 2018-11-08. PMID:30103438. |
dpp-iv inhibitors shorten the inactivation of glp-1, permitting the incretin to stimulate insulin release, thereby combating hyperglycemia. |
2018-11-08 |
2023-08-13 |
Not clear |
| Emma K Biggs, Lihuan Liang, Jacqueline Naylor, Shimona Madalli, Rachel Collier, Matthew P Coghlan, David J Baker, David C Hornigold, Peter Ravn, Frank Reimann, Fiona M Gribbl. Development and characterisation of a novel glucagon like peptide-1 receptor antibody. Diabetologia. vol 61. issue 3. 2018-11-05. PMID:29119245. |
glucagon like peptide-1 (glp-1) enhances glucose-dependent insulin secretion by binding to glp-1 receptors (glp1rs) on pancreatic beta cells. |
2018-11-05 |
2023-08-13 |
Not clear |
| Xiao Yue, Jie Liang, Fu Gu, Dongshu Du, Fuxue Che. Berberine activates bitter taste responses of enteroendocrine STC-1 cells. Molecular and cellular biochemistry. vol 447. issue 1-2. 2018-10-30. PMID:29363059. |
glucagon-like peptide-1 (glp-1) is involved in the regulation of insulin secretion and glucose homeostasis. |
2018-10-30 |
2023-08-13 |
Not clear |
| Breanna M McArthur, Richard D Mattes, Robert V Considin. Mastication of Nuts under Realistic Eating Conditions: Implications for Energy Balance. Nutrients. vol 10. issue 6. 2018-10-29. PMID:29865169. |
appetite sensations were measured at regular intervals for 3 h after nut intake, and plasma samples were collected for the measurement of glucose, insulin and glucagon-like peptide-1 (glp-1). |
2018-10-29 |
2023-08-13 |
Not clear |
| Breanna M McArthur, Richard D Mattes, Robert V Considin. Mastication of Nuts under Realistic Eating Conditions: Implications for Energy Balance. Nutrients. vol 10. issue 6. 2018-10-29. PMID:29865169. |
fullness sensations were higher after whole nut than nut butter consumption though there were no significant changes in glucose, insulin, or glp-1 concentrations under any condition. |
2018-10-29 |
2023-08-13 |
Not clear |
| Francisco Tomás Pérez-Durillo, Ana Belén Segarra, Ana Belén Villarejo, Manuel Ramírez-Sánchez, Isabel Priet. Influence of Diet and Gender on Plasma DPP4 Activity and GLP-1 in Patients with Metabolic Syndrome: An Experimental Pilot Study. Molecules (Basel, Switzerland). vol 23. issue 7. 2018-10-16. PMID:29958403. |
insulin, glp-1, and plasma dpp4 were determined within the first 30-min postprandial period. |
2018-10-16 |
2023-08-13 |
Not clear |